AzTrials
AzTrials

Treponema Pallidum InfectionMATCH-POINTNCT07290439

Improving Maternal and Child Health Through Point-of-care STI Testing

A study testing Point-of-care STI tests in people with Treponema Pallidum Infection and Chlamydia Trachomatis Infection, run by Emory University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. Read more about this study

Who is it for?
Any age, women onlyHealthy volunteers can take part
What is being tested?
Point-of-care STI tests
Could I receive a placebo?
No, everyone receives an active treatment
How many people
756 participants
Where
1 siteUnited States
Study dates
11 Aug 2026to Jun 2030
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Pregnant and clinically indicated for STI testing (syphilis and/or Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV) at a prenatal care (PNC ) or labor and delivery (L\&D) triage visit at Grady Memorial Hospital (GMH). Indications for STI testing in pregnancy at GMH:
  • Syphilis, CT, NG, and TV indicated at first PNC visit
  • Syphilis serologic testing additionally indicated in 3rd trimester and at delivery
  • CT/NG/TV additionally indicated in the 3rd trimester for those <25 or with increased risk [1]
  • Additional testing recommended based on clinical signs or symptoms (e.g., genital lesion or vaginal discharge, new exposure history)
  • English or Spanish-speaking
Show all 19Show fewer
  • If <16 years of age, has a parent or legal guardian present
  • Have STI risk factor:
  • <25 years of age
  • Reports current substance use
  • Reported or documented history of a positive STI
  • More than one current sex partner
  • A current sex partner who has concurrent partners
  • A new sex partner (<6 months )
  • A current sex partner who has an STI
  • Exchange of sex for money or drugs
  • Incarceration
  • No previous prenatal care during the current pregnancy
  • Able to follow study procedures and provide written informed consent or assent, as appropriate

Who cannot join

  • Indicated for syphilis test: negative RPR test during this pregnancy
  • Indicated for syphilis test: ever had a previous syphilis diagnosis (lifetime history)
  • Indicated for CT/NG/TV test: negative for all three of CT, NG, and TV within the previous 1 month
  • Indicated for CT/NG/TV test: positive for any of CT, NG, and/or TV and completed treatment <3 weeks prior
  • Stakeholders:
  • GMH PNC or L\&D providers, GMH leadership, Georgia Dept of Health leadership
  • >=18 years of age
  • Able to follow study procedures and provide verbal informed consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Kristin Wall, PhD contact

(404)-616-0600

kmwall@emory.edu

Kimberly Workowski, MD contact

kworkow@emory.edu

United States1 site, 1 recruiting
  • Grady Memorial Hospital

    Atlanta, Georgia, 30303

    Kimberly Workowski, MD, 404-686-7893, kworkow@emory.edu

    Kimberly Workowski, MD

    Recruiting

Other trials in United States

About this study

Official title: Improving Maternal and Child Health Through Point-of-care STI Testing (MATCH-POINT)

The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. It will also learn about the feasibility, acceptability, and cost-effectiveness of implementing POCTs in a large safety-net hospital setting.

The main questions it aims to answer are:

Read more
  • Do POCTs reduce delays in STI treatment compared with standard laboratory-based testing?
  • What barriers, facilitators, and processes affect POCT implementation in prenatal and obstetric care?
  • What are the costs and cost-effectiveness of POCTs compared with standard testing?

Participants will:

  • Complete a baseline survey and receive either POCTs (fingerstick blood draw or vaginal swab) or standard laboratory STI testing.
  • If diagnosed with an STI, complete a follow-up survey approximately one month later.
  • Stakeholders (providers, hospital leadership, and public health officials) will complete interviews to inform implementation strategies.
Read the detailed description

Sexually transmitted infections (STIs) represent a growing public health crisis in the United States, with disproportionate impact among Black women and women residing in the Southeastern region. National surveillance data demonstrate alarming increases in syphilis, with reported cases rising by 937% and congenital syphilis cases increasing by 755% over the past decade. In pregnant women, untreated or delayed treatment of STIs is associated with severe adverse reproductive outcomes, including stillbirth, preterm birth, and vertical transmission to the infant.

At Grady Memorial Hospital (GMH), a large safety-net hospital in Atlanta, Georgia, the current standard of care for syphilis diagnosis relies on rapid plasma reagin (RPR) screening, confirmatory treponemal testing, and patient history. This process requires patient recontact for counseling, treatment initiation, and partner notification. Similarly, testing for chlamydia (CT), gonorrhea (NG), and trichomonas (TV) is performed using laboratory-based nucleic acid amplification tests (NAATs), which typically require 1-3 days for results. The absence of same-day diagnostic results creates significant barriers to timely treatment, as recontacting patients is often challenging, and transportation or socioeconomic constraints may limit access to care.

STI counseling and treatment at GMH are provided by the clinical team in accordance with the Centers for Disease Control and Prevention (CDC) STI Treatment Guidelines. Recommended regimens include intramuscular benzathine penicillin G (single dose for early syphilis; three weekly doses for latent or unknown duration syphilis), oral azithromycin for chlamydia in pregnancy, intramuscular ceftriaxone for gonorrhea, and a one-week course of oral metronidazole for trichomonas. Patients with positive results are retested per GMH standard of care, consistent with CDC recommendations.

Despite adherence to national guidelines, treatment delays remain common among pregnant women presenting to GMH's outpatient prenatal care (PNC) clinic and Labor \& Delivery (L\&D) triage. These delays increase risk of onward transmission, including mother-to-child transmission, and contribute to adverse reproductive outcomes.

To address these challenges, multidisciplinary experts in obstetrics, infectious diseases, clinical trials, and implementation science at Emory University have developed the MATCH-POINT study. This study will evaluate the effectiveness and scalability of point-of-care tests (POCTs) for syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women receiving care at GMH. GMH serves a predominantly under-resourced patient population with high STI prevalence and elevated maternal and child morbidity and mortality.

Findings from MATCH-POINT will inform strategies for integrating POCTs into routine prenatal and obstetric care, with the goal of reducing treatment delays, improving maternal and infant outcomes, and preventing onward transmission. Results will be shared with key stakeholders, including the Georgia Department of Public Health, to guide recommendations for broader implementation and scalability of POCTs across safety-net hospitals and clinics serving under-resourced pregnant women throughout the Southeastern United States.

Being tested
Point-of-care STI tests, Standard of care STI testing
Keywords
Prenatal care, Point of care test
Medical subject headings
Syphilis, Gonorrhea, Trichomonas Vaginitis, Sexually Transmitted Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Point-of-care STI testsDiagnostic test

    Point-of-care testing for syphilis and/or chlamydia, gonorrhea, and trichomonas, depending on clinical indication at the visit.

    Testing will be performed using the Syphilis Health Check (SHC) and/or the Visby Sexual Health Test.

    • Syphilis Health Check (SHC)
    • Single-use, disposable, fully integrated rapid test.
    • Provides results in approximately 10 minutes.
    • Detects syphilis antibodies (IgM and IgG to treponemal antigens) from fingerstick, whole blood, serum, or plasma.
    • Visby Sexual Health Test (Visby Medical):
    • Single-use, disposable, fully integrated rapid PCR-based assay.
    • Provides results in <30 minutes.
    • Detects Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis from vaginal swabs.
  • Standard of care STI testingDiagnostic test

    Also called SOC

    Standard of care for STI testing

    Testing procedures:

    • Blood samples will be collected for syphilis screening using rapid plasma reagin (RPR) with reflex treponemal testing.
    • Vaginal swab samples will be collected for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) testing using nucleic acid amplification tests (NAATs).
Study groups in NCT07290439
Study groupRoleWhat they receive
Control armActive comparatorParticipants will undergo routine clinical care at Grady Memorial Hospital (GMH), consistent with CDC STI Treatment Guidelines. * Positive results will be communicated via phone and/or Patient Portal. * For trichomoniasis or chlamydia, treatment will involve sending a prescription to the patient's preferred pharmacy. For syphilis or gonorrhea, patients will be asked to return to the clinic for an antibiotic infection.
Receives: Diagnostic Test: Standard of care STI testing
Intervention armExperimentalIf participants wait for POCT results: * Positive results will prompt same-day counseling and treatment. * Treatment will be directly observed for gonorrhea and syphilis, or provided as a same-day prescription for trichomonas. * Chlamydia treatment may be directly observed or prescribed, depending on the clinical setting, consistent with the standard of care. If participants do not wait for POCT results: * Positive results will be communicated via phone and/or Patient Portal. * Treatment will proceed as in the standard-of-care control arm.
Receives: Diagnostic Test: Point-of-care STI tests; Diagnostic Test: Standard of care STI testing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to treatment

    Percentage of participants with onset of treatment within 1 week vs in more than a weeks time frame.

    Time from STI diagnosis to medication administered (syphilis, NG, and some CT infections) or prescription written (TV and some CT infections)

    Measured: Baseline (STI testing), up to pregnancy completion (up to 41 weeks)

Secondary outcomes (9)
  1. Time to STI treatment completion

    Time between STI diagnosis and:

    • Treatment completion
    • Prescriptions being filled
    • Partner STI treatment Pregnancy outcomes Follow-up testing Linkage to care

    Measured: Baseline (STI diagnosis) and 1 month follow-up

  2. Repeat STI positives

    Number of participants testing positive for the same infection documented a second time meeting the following criteria: there was documentation of appropriate treatment between those diagnoses, and there were at least 4 weeks between tests.

    Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)

  3. Stillbirths

    The number of stillbirths will be reported. This is defined as fetal death occurring at ≥20 weeks' gestation.

    Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)

  4. Miscarriage

    The number of miscarriages will be reported. This is defined as a spontaneous loss of pregnancy before 20 weeks' gestation.

    Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)

  5. Ectopic pregnancy

    Number of ectopic pregnancies will be reported. This is defined as implantation of the pregnancy outside the uterine cavity (e.g., fallopian tube, ovary, abdominal cavity).

    Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)

  6. Preterm Birth

    Number of preterm births will be reported. This is defined as live birth occurring before 37 completed weeks of gestation.

    Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)

  7. Pre mature rupture of membranes

    Number of cases of premature rupture of membranes (PROM) will be reported. This is defined as spontaneous rupture of amniotic membranes before the onset of labor.

    Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)

  8. Chorioamnionitis

    Number of cases of chorioamnionitis will be reported. This is defined as intra-amniotic infection characterized by maternal fever plus clinical signs (e.g., uterine tenderness, maternal/fetal tachycardia, purulent amniotic fluid).

    Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)

  9. Postpartum endometritis

    Number of cases of postpartum endometritis will be reported. This is defined as infection of the endometrium occurring after delivery, typically presenting with fever, uterine tenderness, and foul-smelling lochia

    Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Dec 2025
  2. Study start11 Aug 2026
  3. Primary completionJun 2029 (estimated)
  4. Study completionJun 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
756 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07290439
Sponsor's protocol ID
2025P013591
Other IDs
R01MD020754
Acronym
MATCH-POINT
Status last verified
Aug 2026
First submitted
15 Dec 2025
Last updated
19 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: Minimal, de-identified datasets sufficient to recreate primary analyses will be made publicly available in the repository. The raw data and a data dictionary will be made available in the repository.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in